Eaton Corp plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Eaton Corp plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Feb 22, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Feb 22, 2017 |
| FY2016 | Dec 31, 2014 | $0 | Feb 22, 2017 |
| FY2015 | Dec 31, 2013 | $0 | Feb 24, 2016 |
| FY2014 | Dec 31, 2012 | $0 | Feb 26, 2015 |
| FY2013 | Dec 31, 2011 | $0 | Feb 26, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.45B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $24.88B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $23.20B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $20.75B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $19.63B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $17.86B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $21.39B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $21.61B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $20.40B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $19.75B | Feb 27, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $20.40B | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $19.75B | Feb 28, 2018 |
| FY2017 | Dec 31, 2015 | $20.86B | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $22.55B | Feb 22, 2017 |
| FY2015 | Dec 31, 2013 | $22.05B | Feb 24, 2016 |
| FY2014 | Dec 31, 2012 | $16.31B | Feb 26, 2015 |
| FY2013 | Dec 31, 2011 | $16.05B | Feb 26, 2014 |
| FY2012 | Dec 31, 2010 | $13.72B | Feb 28, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.09B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.79B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.22B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.46B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.14B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.41B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $2.21B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $2.15B | Feb 24, 2021 |
| FY2012 | Dec 31, 2012 | $1.22B | Feb 28, 2013 |
| FY2012 | Dec 31, 2011 | $1.35B | Feb 28, 2013 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $3.68B | Feb 26, 2020 |
| FY2019 | Dec 31, 2018 | $3.63B | Feb 26, 2020 |
| FY2019 | Dec 31, 2017 | $3.21B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $2.96B | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $3.13B | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $3.31B | Feb 22, 2017 |
| FY2015 | Dec 31, 2013 | $3.18B | Feb 24, 2016 |
| FY2014 | Dec 31, 2012 | $2.22B | Feb 26, 2015 |
| FY2013 | Dec 31, 2011 | $2.26B | Feb 26, 2014 |
| FY2012 | Dec 31, 2010 | $1.70B | Feb 28, 2013 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $797.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $794.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $754.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $665.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $616.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $551.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $606.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $584.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $584.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $587.00M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.31B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.08B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.80B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.23B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.26B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $3.08B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $3.58B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $3.55B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $3.53B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $3.46B | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.47B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.33B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.62B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.53B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.16B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $2.94B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $3.45B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $2.66B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $2.67B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $2.57B | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $919.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $808.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $757.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $598.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $575.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $389.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $587.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $565.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $520.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $497.00M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.25B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $38.38B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $38.43B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $35.01B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $34.03B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $31.82B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $32.81B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $31.09B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $32.62B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $30.48B | Feb 27, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.43B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.49B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $19.04B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $17.04B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $16.41B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $14.93B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $16.08B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $16.11B | Feb 26, 2020 |
| FY2018 | Jan 1, 2018 | $17.25B | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $17.25B | Feb 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.77B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $14.71B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $14.98B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $14.80B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $14.75B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $12.90B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $13.46B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $13.33B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $13.57B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $13.20B | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.70B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.10B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $10.31B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.47B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $7.59B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $6.79B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $8.17B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $8.16B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $8.67B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $7.56B | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $622.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $555.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $488.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $294.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $297.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $438.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $370.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $283.00M | Feb 26, 2020 |
| FY2019 | Dec 31, 2017 | $561.00M | Feb 26, 2020 |
| FY2019 | Dec 31, 2016 | $543.00M | Feb 26, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.89B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.15B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $9.26B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.33B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $8.57B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $8.06B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $8.07B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $7.11B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $7.75B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $8.26B | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 6 | Feb 26, 2020 |
| FY2017 | Sep 30, 2017 | 3 | Feb 28, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 6 | Feb 26, 2020 |
| FY2017 | Sep 30, 2017 | 3 | Feb 28, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 387.90M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 392.90M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 399.40M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 397.80M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 398.80M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 398.10M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 413.30M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 423.60M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 439.90M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 449.40M | Feb 28, 2018 |